


# Repræsentantskabs møde


## 25-1-2010

Susanne Møller  
DBCG


# Antal i DBCG 89/99/01/04/07/09 pr år (n=68.478)



# Antal registreringer af pt. med primær invasiv cancer i DBCG vs CR vs Patobank




# Fundet ved populationsscreening



DBCG, SM


# Fordeling af alder pr år



DBC, SM

# Fordeling af tumorstørrelse pr år


(største diameter i mm)



DBCg, SM


# Fordeling af tumorstørrelse pr år

(største diameter i mm- ny inddeling)



DBCg, SM


# Fordeling af operationstype pr år



DBCG, SM




# Fordeling af præoperativ klassifikation



DBCG, SM

# Fordeling på protokol pr år



DBCG, SM

# Fordeling på protokoller i 2009

Protokol	Kriterier	Medicinsk efterbeh.	Antal (n=5037)
Ikke i protokol			31 (1.%)
A	Lavrisiko: >35 år N-, tumor<=2 cm (duktal, I or lobulær I-II or Anden diag) R+/? , HER2 -/? , Top2A normal/?	Ingen	975 (20%)
B,t	<60 år, R+/R?, HER2 +	KT, ET, T	167 (3.3%)
B	<60 år, R+/R?, HER2 -/?	KT,ET	916 (18%)
C	>=60 år, R+/R?	ET	1599 (32%)
D,t	R-, HER2 +	KT, T	211 (4.2%)
D	R-, HER2 -/?	KT	418 (8.3%)
Ikke bestemt			720 (15%)

DBCG, SM

# Årsager til ikke protokol i 2009 ,


(n =31+ 720, færre udfyldte efter on-line)

Årsag	Antal 2009 (2008)	Andel af xxx pt.
<b>Fjernmetastaser</b>	<b>50 (59)</b>	
Tidl.malign	91 (77)	
<b>Sarkom/phylloides</b>	<b>3 (4)</b>	
Bilateral	97 (103)	
Kontraindikation (f.eks. Alder)	61 (109)	
Teknisk inoperabel	40 (79)	
Ikke opereret ifølge dbcg	157 (303)	
<b>Andet</b>	<b>69 (142)</b>	
<i>Død &lt;4 uger efter operation</i>		
<i>Fejlbehandlet / fejlklassificeret</i>		
<i>fravalg</i>		
DBCG, SM		

# Randomiserede protokoller i 2009

Protokol	Regime	2007-2008 antal	2009 (+2010) antal
READ start juli 08	1 EC → Docetaxel 2 Docetaxel+ Cyklofosfamid	77	459
ALTTO start nov 07	1 Trastuzumab 2 Lapatinib 3 Trastuzumab → Lapatinib 4 Trastuzumab + Lapatinib	150	10
REAL start juli 09	Operation -> letrozol Neo_adj 4 uger -> operation		18
RT 09 Stråle beh Start sept 09			152
SOLE Start nov 09	Fortsat letrozole efter 5 år Continuert vs intermitterende		18


# Antal positive lymfeknuder pr år



DBCG, SM

# Malignitetsgrad 1-3 pr år


(ductal tumor n=38.715)



DBCG, SM

# Malignitetsgrad 1-3 pr år


(lobulær tumor n=2990 ( ca 350 pr år))



DBCg, SM




# Receptorstatus pr år



DBCG, SM


# HER2 status pr år (2002-2008)



DBCG, SM

# TOP2A bestemmelser


2008 (n=375) og 2009 (n=1825)



DBC, SM


# TOP2A bestemmelser

2008 (n=375) og 2009 (n=1825)




# Comorbiditet

( 1991-2008 : n=300 , 2009 : n=3609)




DBC, SM

# Sentinel Node pr år (Node -/+) efter 2002



DBCg, SM

# Antal påviste lymfeknuder pr år




DBCg, SM

# Antal påviste lymfeknuder pr år

## Ikke Sentinel Node


(-SN eller +SN,N-pos)



DBCg, SM




# Antal påviste lymfeknuder pr år med Sentinel Node (SN, N-neg)



DBCG, SM

# Fordeling af diagnosetype pr år



DBCG, SM